Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC switch

This article was originally published in The Tan Sheet

Executive Summary

"The future promises increases in the number of drugs available OTC and in the variety of indications for their use," Eric Brass, MD/PhD, Harbor-UCLA Medical Center, writes in Sept. 13 NEJM. Former NDAC Chairman asserts technology advances may facilitate OTC therapy growth, noting "the wide availability and acceptance of reliable methods of measuring serum cholesterol in nonmedical settings may eventually contribute to the safety and effectiveness of OTC treatments for hyperlipidemia." Brass, whose term on NDAC ended in May, presided over the committee's consideration and rejection of switch applications for the statins Pravachol (BMS) and Mevacor (Merck) in July 2000
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS093042

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel